Abstract library

15 results for "Preto".
#46 Neuroendocrine markers are expressed in human mammary glands
Introduction: Regulatory peptides have previously been detected in epithelial cells of human mammary glands. As these peptides are produced by scattered neuroendocrine cells in the epithelium of other tissues the aim of this study was to investigate whether the mammary glands express molecular markers for neuroendocrine cells.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Malin Grönberg
#163 Clinical value of MRI DWI and (Gd-EOB)-DTPA to assess liver involvement in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Introduction: Standard MRI, including breath-hold techniques with SE T1 and T2 weighted images, biochemical shift, and 3D GRE and also T1 images after gadolinium enhancement Gd-DTPA, are useful in detecting liver lesions in patients with advanced GEP-NET. Recently, new algorithms of MRI, including diffusion-weighted imaging MRI (DWI) and i.v. (Gd-EOB)-DTPA (Primovist) contrast enhancement, seems to be promising in the detection of liver deposits.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jaroslaw B Cwikla
#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Carlos A. S. Soares
#362 Succinate Dehydrogenase (SDH) Complex Expression in Pancreatic Endocrine Tumours (PETs)
Introduction: Absence of SDH subunit D (SDHD) mutations were reported by Perren et al (Oncogene 2002) but loss of heterozigosity (LOH) was described in 29% of the PETs. Since SDHD gene may depict a form of genomic imprinting in neuroendocrine (NE) tissue, the reported LOH may drive activation of the hypoxia pathway. Taking advantage from the immunohistochemical (IHC) method for genetic triage we may deduce the mutational status of SDH subunits (A, B, C and D) based on IHC SDHB expression. These subunits are striking candidates as they are mutated in other NE neoplasias.
Conference:
Category: Basic
Presenting Author: Mr João Vinagre
Authors: Vinagre J, Preto J, Soares P, Lopes J M, ...
Keywords: PETs SDH LOH
#782 Appendix Well-Differentiated Neuroendocrine Tumors (A-WDNETs) at a Large Tertiary Center: Clinical-Pathological Features and Long-Term Follow-Up Evaluation
Introduction: A-WDNETs comprise 32-57% of appendix tumors, diagnosed incidentally in 0.3-0.9% appendectomies (AP). Overall survival is good, but malignant behavior remains controversial.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. John Preto
#1229 Preliminary Results on the Diagnosis of NETs in Portugal – The Cross Sectional TNE-ETC Survey
Introduction: NETs are increasing worldwide. Epidemiological data is lacking in Portugal. The NETs Study Group of the Portuguese Endocrine Society is committed to develop a National Registry.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD, MSc Ana P Santos
Keywords: Portugal NET
#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)
Introduction: SSA are the first line therapy in well differentiated pNET
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Md, PhD Agnieszka Kolasińska-Ćwikla
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#265 A Novel PKCßII Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells
Introduction: Deregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Chiara Zatelli
#366 Next Generation Sequencing is a Cost Effective and Time Saving Method in Clinical Genetic Screening of Patients with Pheochromocytomas
Introduction: Pheochromocytomas are rare tumours arising from adrenal medulla. Recent findings show that about 30-40% of pheochromocytomas are caused by germline mutations in one of the ten hereto known susceptibility genes: SDHA, SDHB, SDHC, SDHD, SDHAF2, RET, VHL, NF1, TMEM127 and MAD. This list of genes is constantly growing. These ten genes together consist of 128 exons and a genetic screening test is both extensive time-consuming and expensive. We introduce utilizing Next generation sequencing as a fast and cost effective method.
Conference:
Category: Basic
Presenting Author: Mr. Joakim Crona